SEC EDGAR CompanyFacts fact · point in time
Akari Therapeutics, Plc: cash_and_restricted_cash
One fact, its scope and the complete path back to the official record.
Reported value
$9.361M{"amount": 9361000, "concept": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "currency": "USD"}- Entity
- Akari Therapeutics, Plc
- Metric
- cash_and_restricted_cash
- Period
- as of 2021-12-31
- Status
- superseded
- Source
- SEC EDGAR CompanyFacts
Provenance
Source licenseUS-PD-17USC105
Retrieved2026-08-19T15:38:54.169101+02:00
Raw response SHA-256
f7bde1a401b286c74a2fd824ee1df541…Official-identifier path
https://factanker.com/fact/sec/cik-0001541157/cash-and-restricted-cash/2021-12-31 (CIK, metric, reporting date)History
- supersedes {"amount": 9361270, "concept": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "currency": "USD"} (evidence 0001410578-22-001546)
Why this page exists
The UUID above is the stable citation anchor: it never changes, and corrections supersede rather than overwrite. Cite the URL and any reader — human or machine — can verify the value against the official filing.